Details for New Drug Application (NDA): 020548
✉ Email this page to a colleague
NDA 020548 describes FLOVENT, which is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in four NDAs. There is one patent protecting this drug. Additional details are available on the FLOVENT profile page.
The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for 020548
| Tradename: | FLOVENT |
| Applicant: | Glaxosmithkline |
| Ingredient: | fluticasone propionate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.044MG/INH | ||||
| Approval Date: | Mar 27, 1996 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.11MG/INH | ||||
| Approval Date: | Mar 27, 1996 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, METERED;INHALATION | Strength | 0.22MG/INH | ||||
| Approval Date: | Mar 27, 1996 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
